AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1992
Founded1992
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
241.88B
Market cap241.88B
Price-Earnings ratio
34.19
Price-Earnings ratio34.19
Dividend yield
1.96%
Dividend yield1.96%
Average volume
6.17M
Average volume6.17M
High today
$77.69
High today$77.69
Low today
$76.74
Low today$76.74
Open price
$76.87
Open price$76.87
Volume
4.92M
Volume4.92M
52 Week high
$87.68
52 Week high$87.68
52 Week low
$62.75
52 Week low$62.75

AZN News

Seeking Alpha 2h
AstraZeneca to buy EsoBiotec to advance cell therapy ambition

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN), it said on Monday. The EsoBiotec Engineered NanoBody Lentivira...

AstraZeneca to buy EsoBiotec to advance cell therapy ambition
TipRanks 2h
AstraZeneca’s Eneboparatide Shows Promise in Phase III Trial for Hypoparathyroidism

The latest update is out from AstraZeneca ( (GB:AZN) ). AstraZeneca announced that its investigational drug eneboparatide met the primary endpoint in the Phase...

TipRanks 3d
Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating

Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Cellectis SA (CLLS – Research Report). The associated price target is $6.00. Silv...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
15.2%
Sell
0%

More AZN News

TipRanks 7d
AstraZeneca’s Promising Pipeline and Market Potential Drive Buy Rating Amid Positive Competitor Data

Morgan Stanley analyst Sarita Kapila has maintained their bullish stance on AZN stock, giving a Buy rating today. Sarita Kapila has given her Buy rating due to...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.